

**Annexure-1****Decisions of 349 EC (27.6.2021)**

The decision of the PCI are as under. It is further decided that -

- a) Wherever needed inspections will be carried out subsequently and if the facts claimed by the institution are found false, the PCI may change or withdraw the approval.
- b) Any approval granted by the PCI beyond 2021-2022 academic session will stand but will be considered year on year basis based on the information submitted by institution in online SIF.
- c) Wherever required, institution shall furnish additional information as sought by the PCI from time to time.
- d) The request for raise in admissions for D.Pharm course beyond 60 intake is not considered as per the policy of the council.
- e) Regarding M.Pharm seats, it was noted that 110 Central Council in its meeting held on 11th December, 2020 under item No.273 decided as under -
  - i) 12 specialties / subjects are prescribed in which M.Pharm can be conducted. (Ref: Regulation-9., Appendix-A of M.Pharm Regulations).
  - ii) maximum 15 seats per specialization are sanctioned by PCI (Ref: Regulation-23.(1) of M.Pharm Regulations)  
Further as per the statutory provisions of M.Pharm Regulations, the ratio of recognized Post-Graduate teacher to number of students to be admitted for the M.Pharm course shall be 1:3.
  - iii) as per the procedure in vogue, the institution applies in SIF for number of seats per specialization / raise in admission in case number of seats sanctioned by PCI are less than 15.
  - iv) In view of above statutory provisions of the M.Pharm Regulations, it was decided that in case institution has the prescribed teaching staff with prescribed experience as per "The Master of Pharmacy (M.Pharm) Course Regulations, 2014", PCI shall sanction number of admissions per M.Pharm specialization based on availability of the teaching staff irrespective of institution's request in SIF. However, under no circumstances more than 15 students per specialization shall be sanctioned.  
In view of above, M.Pharm seats are decided accordingly.
- f) The institution shall not make any admission to the increased intake sanctioned by PCI without affiliation of the Examining Authority for raise in admission.

349/EC Item No.	Reference No.	Institute Name/ ID	349 EC (27.6.2021) Decision	Examining Authority / Hospital
		PCI – 4354  B.Pharm	2nd year for B.Pharm course.  Allowed 100 admissions in 2021-2022 in 1st year (B.Pharm)  Permit raise in admission from 60 to 100 from 2021-2022 academic session.	Anna Salai, Guindy, Chennai - 600 032.
175	510/ TN-117 / 2021- 2022  112 <sup>th</sup> CC	<b>Tamil Nadu</b> J K K Munirajhh Medical Research Foundation Annai J K K Sampoorani Ammal College Of Pharmacy Ethirmediu B Komarapalayam Namakkal District  PCI – 962  M.Pharm	The latest information on record including appeal was placed and considered.  <u><b>M.Pharm</b></u>  M.Pharm (Regulatory Affairs) – 15  M.Pharm (Pharmacognosy) – 12	<u><b>M.Pharm</b></u> The Registrar The Tamil Nadu Dr. M.G.R. Medical University, No.69, (Old No.40), P.B. No. 1200, Anna Salai, Guindy, Chennai - 600 032.
176	517/ TN-122 / 2021- 2022  112 <sup>th</sup> CC	<b>Tamil Nadu</b> Sri Vijay Vidyalaya College of Pharmacy Nallampalli Dharmapuri  PCI – 2349  Pharm.D Pharm.D (PB) M.Pharm	The latest information on record including appeal was placed and considered.  It is noted that it is an existing institution.  <u><b>Pharm.D</b></u> Granted approval for 2021-2022 academic session for conduct of 1st year for 30 admissions for Pharm.D course.  <u><b>Pharm.D (PB)</b></u> Granted approval for 2021-2022 academic session for conduct of 4 <sup>th</sup> year for 10 admissions for Pharm.D (PB) course.	<u><b>Pharm.D, Pharm.D (PB) and M.Pharm</b></u> The Registrar The Tamil Nadu Dr. M.G.R. Medical University, No.69, (Old No.40), P.B. No. 1200, Anna Salai, Guindy, Chennai - 600 032.  <u><b>Hospital</b></u> Government Dharmapuri Medical College and Hospital, Dharmapuri Tamilnadu

**Annexure-3 of Item No.8 (1-898)**  
**112<sup>th</sup> CC Meeting (10.6.2021)**

1. The decision of the PCI are as under.
2. It is decided that decisions are subject to following conditions.
  - a) the consent of affiliation of the Examining Authority and NOC of the State Government (as applicable) should be available with the institution.
  - b) the institution should have a legal entity status on the date of application to PCI and NOC of the State Government and consent of affiliation of Examining Authority (as applicable) shall be in the name of legal entity.
  - c) They shall produce records of their legal entity and the land and building documents to substantiate their claims.
  - d) Wherever needed inspections will be carried out subsequently and if the facts claimed by the institution are found false, the PCI may change or withdraw the approval.
  - e) Any approval granted by the PCI beyond 2021-2022 academic session will stand but will be considered year on year basis based on the information submitted by institution in online SIF.
  - f) Wherever required, institution shall furnish additional information as sought by the PCI from time to time.
  - g) The request for raise in admissions for D.Pharm course beyond 60 intake is not considered as per the policy of the council.
  - h) Regarding M.Pharm seats, it was noted that 110 Central Council in its meeting held on 11th December, 2020 under item No.273 decided as under -
    - i) 12 specialties / subjects are prescribed in which M.Pharm can be conducted. (Ref: Regulation-9., Appendix-A of M.Pharm Regulations).
    - ii) maximum 15 seats per specialization are sanctioned by PCI (Ref: Regulation-23.(1) of M.Pharm Regulations)  
Further as per the statutory provisions of M.Pharm Regulations, the ratio of recognized Post-Graduate teacher to number of students to be admitted for the M.Pharm course shall be 1:3.
    - iii) as per the procedure in vogue, the institution applies in SIF for number of seats per specialization / raise in admission in case number of seats sanctioned by PCI are less than 15.
    - iv) In view of above statutory provisions of the M.Pharm Regulations, it was decided that in case institution has the prescribed teaching staff with prescribed experience as per "The Master of Pharmacy (M.Pharm) Course Regulations, 2014", PCI shall sanction number of admissions per M.Pharm specialization based on availability of the teaching staff irrespective of institution's request in SIF. However, under no circumstances more than 15 students per specialization shall be sanctioned.  
In view of above, M.Pharm seats are decided accordingly.
    - v) The institution shall not make any admission to the increased intake sanctioned by PCI without affiliation of the Examining Authority for raise in admission.
3. The above conditions be also conveyed to individual institution through the institution's dash board.

Item.No.	Institute Name / ID	112 CC (10.6.2021) Decision	Examining Authority/ Hospital
----------	---------------------	-----------------------------	----------------------------------

		In view of above, it was decided to reject the application for introduction of M.Pharm course.	
510/ TN-117 / 2021- 2022	<p>J K K Munirajhh Medical Research Foundation Annai J K K Sampoorani Ammal College Of Pharmacy Ethirmediu B Komarapalayam Namakkal District</p> <p>PCI – 962</p> <p>D.Pharm B.Pharm Pharm.D M.Pharm</p>	<p>1. Extension of approval upto 2021-2022 academic session for 60 admissions for D.Pharm course.</p> <p>2. Extension of approval upto 2021-2022 academic session for 100 admissions for B.Pharm course.</p> <p>3. Extension of approval upto 2021-2022 academic session for 30 admissions for Pharm.D course.</p> <p>4. M.Pharm course – M.Pharm (Pharmaceutics) – 15 M.Pharm (Pharmaceutical Chemistry) – 10 M.Pharm (Pharmaceutical Analysis) - 10 M.Pharm (Pharmacy Practice) – 15 M.Pharm (Pharmacology) - 15</p> <p><b>Regarding introduction of new M.Pharm (Regulatory Affaris and Pharmacognosy) course.</b></p> <p>It was noted that Institution has failed to submit consent of affiliation of Examining Authority for introduction of new M.Pharm (Regulatory Affaris and Pharmacognosy) course.</p> <p>In view of above it was decided to reject the application for introduction of new (Regulatory Affaris and Pharmacognosy).</p>	<p><b><u>D.Pharm</u></b> The Director Directorate of Medical Education, 162, Poonamallee High Road Kilpauk, Chennai – 600 010.</p> <p><b><u>B.Pharm, Pharm.D &amp; M.Pharm</u></b> The Registrar The Tamil Nadu Dr. M.G.R. Medical University, No.69, (Old No.40), P.B. No. 1200, Anna Salai, Guindy, Chennai - 600 032.</p> <p><b><u>Name of the Hospital:-</u></b> Muruthi Medical Centre and hospital, Erode.</p>